| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/28/2006 | US7018999 Administering a stress-activated protein kinase inhibitor, particularly a fused pyrrolocarbazole compound. |
| 03/28/2006 | US7018998 substituted 4,5-dihydro-1H-benzo[b][1,4]-diazepin-2-one; amidation of a substituted monoprotected 1,2-diaminobenzene with an ester, deprotecting, cyclization; chronic neurological disorders, psychosis, schizophrenia, Alzheimer's disease |
| 03/28/2006 | US7018988 Pharmaceutically active pyrrolidine derivatives as Bax inhibitors |
| 03/28/2006 | US7018985 Composition and method for inhibiting platelet aggregation |
| 03/28/2006 | US7018797 Method for treating neurodegenerative disorders |
| 03/28/2006 | US7018662 Palliative effects of morinda citrifolia oil and juice |
| 03/28/2006 | US7018620 Delivery of beta-blockers through an inhalation route |
| 03/28/2006 | US7018619 Administering a therapeutic amount of an alprazolam, estazolam, midazolam or triazolam condensation aerosol for therapy of anxiety or insomnia |
| 03/28/2006 | US7017573 Methods and apparatus for relieving headaches, rhinitis and other common ailments |
| 03/28/2006 | CA2415750C Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 03/28/2006 | CA2343459C Pyrazole derivatives as anti-inflammatory/analgesic agents |
| 03/28/2006 | CA2309551C Aminothiazole inhibitors of cyclin dependent kinases |
| 03/28/2006 | CA2242865C Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| 03/28/2006 | CA2147451C 3-indolylpiperidines |
| 03/23/2006 | WO2006031786A2 Protein a compositions and methods of use |
| 03/23/2006 | WO2006031337A2 Combinations of pkc activators and pkc inhibitors for alzheimer’s disease treatment and cognitive enhancement |
| 03/23/2006 | WO2006031267A2 Rna interference suppression of neurodegenerative diseases and methods of use thereof |
| 03/23/2006 | WO2006030975A1 Piperidine derivatives and use thereof |
| 03/23/2006 | WO2006030956A1 NOVEL USE OF PrPP AND RECEPTOR THEREOF |
| 03/23/2006 | WO2006030931A1 N-substituted n-(4-piperidinyl)amide derivative |
| 03/23/2006 | WO2006030898A1 Aldose reductase inhibitor |
| 03/23/2006 | WO2006030805A1 Triazole derivative or salt thereof |
| 03/23/2006 | WO2006030739A1 Process for production of optically active amine derivatives |
| 03/23/2006 | WO2006030306A2 Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder |
| 03/23/2006 | WO2006030300A2 Processes for the preparation of olanzapine |
| 03/23/2006 | WO2006030249A1 Donepezil salts suitable for the preparation of pharmaceutical compositions |
| 03/23/2006 | WO2006030032A1 Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
| 03/23/2006 | WO2006030013A1 The modulation of phagocytosis in neurons |
| 03/23/2006 | WO2006029980A1 Substituted bicyclic imidazo-3-ylamine compounds |
| 03/23/2006 | WO2006029906A1 Methylene dipiperidine derivatives |
| 03/23/2006 | WO2006029852A1 Polypeptide species useful for the treatment of neurological disorders |
| 03/23/2006 | WO2006029850A1 Hydrazone derivatives and their use as beta secretase inhibitors |
| 03/23/2006 | WO2006008133A3 Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| 03/23/2006 | WO2006000844A3 Hydrocephalus treatment |
| 03/23/2006 | WO2005121078A3 Substituted cyclopentene compounds |
| 03/23/2006 | WO2005046658A3 Methods of modulating angiogenesis and cancer cell proliferation |
| 03/23/2006 | US20060064767 Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy |
| 03/23/2006 | US20060063940 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 03/23/2006 | US20060063934 Pyrazole compounds |
| 03/23/2006 | US20060063932 Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis |
| 03/23/2006 | US20060063843 Compounds for the treatment of inflammatory disorders |
| 03/23/2006 | US20060063810 Combination treatment for impaired motor function in parkinson's disease |
| 03/23/2006 | US20060063793 Method of inhibiting neurotrophin-receptor binding |
| 03/23/2006 | US20060063789 Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors |
| 03/23/2006 | US20060063788 Carbon monoxide dependent guanylyl cyclase modifiers and methods of use |
| 03/23/2006 | US20060063778 2(R)-Benzyloxymethyl-4-[4-(4-chloro-phenyl)-piperazin-1-yl]-N-hydroxy-3(S)-(4-methoxy-phenyl)-4-oxo-butyramide; inhibiting matrix metalloproteinase; immunosuppression; neuropathic pain |
| 03/23/2006 | US20060063772 New compounds |
| 03/23/2006 | US20060063771 CCR5 antagonists useful for treating AIDS |
| 03/23/2006 | US20060063763 Compounds and methods for modulating CXCR3 function |
| 03/23/2006 | US20060063762 Indole indazole and benzazole derivative |
| 03/23/2006 | US20060063759 e.g. 5-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl)-3H-benzooxazol-2-one; antiinflammatory, antidiabetic agent; electrolytes and water retention modulator; hypotensive, hypoglycemic agent; arrhythmias, myocardial fibrosis, osteoporosis, polyuria, polydipsia, Crohn's disease |
| 03/23/2006 | US20060063757 Sulfonamide derivatives as antipsychotic agents |
| 03/23/2006 | US20060063753 Use of nefopam for the treatment of nausea or emesis |
| 03/23/2006 | US20060063748 Methods for treating psychosis associated with interferson-alpha therapy |
| 03/23/2006 | US20060063717 Novel inhibitor of beta amyloid cleavage |
| 03/23/2006 | US20060063699 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 03/23/2006 | US20060063235 DNA encoding the human serine protease C-E |
| 03/23/2006 | US20060062856 Controlled release galantamine composition |
| 03/23/2006 | US20060062807 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
| 03/23/2006 | US20060062802 Medicinal product |
| 03/23/2006 | US20060062777 Inhibit tumor growth, or metastasis by modifying protein-protein interactions involving certain amino acid sequences within matrix metalloproteinase 9 (MMP-9) |
| 03/23/2006 | US20060062771 Therapeutic autologous-cell delivery support system, financial system for use therewith, and method therefor |
| 03/23/2006 | DE10318714B4 Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches Drug combinations and therapies to combat alcohol abuse |
| 03/23/2006 | DE102004036641A1 Verzögert freisetzende pharmazeutische Zusammensetzung, die Venlafaxin enthält The sustained release pharmaceutical composition containing venlafaxine |
| 03/23/2006 | CA2764314A1 Process for production of optically active amine derivatives |
| 03/23/2006 | CA2581144A1 Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
| 03/23/2006 | CA2581076A1 D-methionine formulation with improved biopharmaceutical properties |
| 03/23/2006 | CA2580517A1 Protein a compositions and methods of use |
| 03/23/2006 | CA2580409A1 Triazole derivative or salt thereof |
| 03/23/2006 | CA2580251A1 Substituted bicyclic imidazo-3-yl-amine compounds |
| 03/23/2006 | CA2580131A1 Substituted aniline derivatives |
| 03/23/2006 | CA2579964A1 Composition with preventive or improvement effect on stress-induced brain function impairment and related symptoms or diseases |
| 03/23/2006 | CA2579807A1 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders |
| 03/23/2006 | CA2579472A1 Hydrazone derivatives and their use as beta secretase inhibitors |
| 03/23/2006 | CA2579121A1 Process for production of optically active amine derivatives |
| 03/23/2006 | CA2575788A1 Combination of pkc activators and pkc inhibitors for alzheimer's diseasetreatment and cognitive enhancement |
| 03/22/2006 | EP1637611A1 Method for producing oligosaccharides |
| 03/22/2006 | EP1637600A1 Chromosome 1 gene and gene products related to Alzheimer's disease |
| 03/22/2006 | EP1637592A1 Neuronal progenitor cells, methods to produce them and uses thereof for the therapy of neural defects |
| 03/22/2006 | EP1637589A1 Novel stem cell derived from adult tissue and use thereof |
| 03/22/2006 | EP1637533A1 Substituted thiazolopyrimidines as analgetics |
| 03/22/2006 | EP1637532A1 Fused pyrimidine derivative |
| 03/22/2006 | EP1637531A1 Methanesulfonic acid salt of pyrazolopyrimidine compound, crystal thereof, and process for producing the same |
| 03/22/2006 | EP1637530A1 Therapeutic agent for senile dementia |
| 03/22/2006 | EP1637529A1 Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof |
| 03/22/2006 | EP1637527A1 Cannabinoid receptor modulator |
| 03/22/2006 | EP1637521A1 Novel tricyclic heterocycle compound |
| 03/22/2006 | EP1637517A1 2-aminobicyclo 3.1.0 hexane-2,6-dicarboxylic ester derivative |
| 03/22/2006 | EP1637516A1 Sertraline hydrochloride polymorphs |
| 03/22/2006 | EP1637515A1 Sertraline hydrochloride polymorphs |
| 03/22/2006 | EP1637185A1 Controlled-release formulations containing tryptophan and/or its metabolites |
| 03/22/2006 | EP1637170A1 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| 03/22/2006 | EP1637162A1 MEDICINAL COMPOSITION FOR PREVENTING OR TREATING Th1 TYPE IMMUNOLOGICAL DISEASE |
| 03/22/2006 | EP1637161A1 REMEDY FOR CEREBRAL NEURODEGENERATIVE DISEASES USING PPAR&dgr; AGONIST |
| 03/22/2006 | EP1637160A2 Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
| 03/22/2006 | EP1637139A2 Novel use of HIV protease inhibiting compounds |
| 03/22/2006 | EP1637138A2 Use of thiazolidinediones to prevent or delay onset of NIDDM |
| 03/22/2006 | EP1637136A1 Composition having autonomic nerve modulating activity and method of use thereof |
| 03/22/2006 | EP1636359A2 Methods for treating pain |
| 03/22/2006 | EP1636260A2 Improved secretion of neublastin |